View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
March 22, 2022

Pipeline Moves: Sorrento terminates Phase Ib CAR-T pancreatic cancer trial, shot at further study drops

Kinnov Therapeutics in alcohol addiction and Genmab in fallopian tube cancer are also reviewed by Clinical Trials Arena.

By Urtė Fultinavičiūtė

As with every Tuesday, the Clinical Trials Arena team brings you this week’s edition of Pipeline Moves. We begin with Sorrento Therapeutics and the termination of its Phase Ib metastatic pancreatic adenocarcinoma trial. We continue with Loxo Oncology’s status update of its Phase I/II cancer study.

Moving on, we cover the trial completions of Kinnov Therapeutics’ Phase II alcohol addiction trial, as well as Genmab’s Phase II cancer study. We close off this week’s edition with Pfizer’s pruritus program.

Would you like to receive these updates in your inbox? Sign-up for our weekly Pipeline Moves newsletter. You can read last Tuesday’s edition here.

Sorrento terminates pancreatic cancer study

Sorrento’s CAR-T asset K-171355 had its Phase Transition Success Rate (PTSR) plummet following the termination of a Phase Ib trial in patients with metastatic adenocarcinoma of the pancreas. The PTSR decreased by 33 points, settling to 33%, after the trial termination. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

According to its ClinicalTrials.gov listing, the Phase Ib trial (NCT03818165) was terminated due to limited participant recruitment. The listing shows it was anticipated to recruit six patients but only recruited two. The study had its status changed to terminated in a ClinicalTrials.gov update on 15 March. GlobalData updated its system on 16 March.  

Loxo updates Phase I/II oncological study

Loxo’s oncology asset LOXO-292 (selpercatinib) saw a rise in its PTSR after a Phase I/II cancer trial’s status was changed to ongoing. The trial is recruiting paediatric participants (patients aged six months to 21 years) with advanced solid or primary central nervous system tumours.

The PTSR increased by 11 points to 23% in solid tumour and 20 points to 33% in central nervous system cancer. GlobalData appraised the asset on 10 March after a ClinicalTrials.gov update on the same day.

The open-label Phase I/II trial (NCT03899792), in collaboration with Eli Lillyis enrolling 100 paediatric subjects. The study will assess dose escalation (Phase I) and dose expansion (Phase II). The asset inhibits the proto-oncogene tyrosine-protein kinase receptor RET and promotes apoptosis in tumour cells.  

Kinnov concludes alcohol addiction trial

Kinnov’s combination of cyproheptadine hydrochloride and prazosin hydrochloride (KT-110) had an increase in its PTSR following the completion of a Phase II trial in patients with alcohol addiction. The PTSR increased by nine points, reaching 25% after the completion of the 154-participant Phase II (NCT04108104) study. The ClinicalTrials.gov listing was updated on 14 March, with asset appraised two days later.  

KT-110 functions as an antagonist of 5-HT2 receptors and alpha1-andrenergic receptions. These receptors mediate excitatory neurotransmission. Alcohol use disorder is characterised by impairment in one’s ability to control or stop alcohol use, regardless of adverse effects to one’s health, social, and occupational life.

Genmab completes Phase II cancer trial

Genmab’s Tivdak (tisotumab vedotin) saw a rise in its PTSR in fallopian tube cancer and epithelial ovarian cancer after the completion of a Phase II trial. The PTSR increased by six points to 42% in both indications. GlobalData appraised the asset on 15 March after a ClinicalTrials.gov update on 11 March.

The Phase II (NCT03657043) enrolled 98 patients with fallopian tube cancer or epithelial ovarian cancer. Tivdak is a tissue factor inhibitor, which inhibits target cell signalling and induces cytotoxicity in tumour cells. Tivdak is approved in previously treated recurrent or metastatic cervical cancer.

Pfizer makes strides in pruritus program

Pfizer’s Cibinqo (abrocitinib) displayed an increase in its PTSR in pruritus after the completion of a Phase I trial recruiting healthy volunteers. The PTSR increased by seven points, reaching 71%, after the completion of the study. The study had its status changed to completed in a ClinicalTrials.gov update on 8 March. GlobalData appraised the asset on 10 March.

The Phase I (NCT05067439) investigated the effect of multiple doses of Cibingo on the pharmacokinetics of caffeine, efavirenz, and omeprazole in 13 healthy subjects. Pruritus (itchy skin) can be a serious dermatological condition characterised by an intense, irritating itching sensation leading to redness, cracked skin, bleeding and infection. Cibingo is approved for treatment of refractory, moderate-to-severe atopic dermatitis.

Additional writing by Clinical Trials Arena healthcare researcher Irena Maragkou

Need to Know:

GlobalData’s proprietary model uses a combination of machine learning and an algorithm to calculate an individual drug’s PTSR. PTSR indicates the probability of a drug’s advancement to the next stage of clinical development. The model uses data points from the individual drugs, clinical trials, regulatory milestones, company, and financial databases.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU